Over the last two decades, human immunodeficiency virus (HIV) infection has been transformed from a short-lived fatal disease to a well-treated disorder, associated with a longer life expectancy. The burden of cardiovascular disease among people living with HIV infection has tripled over this period of time. 1 The underlying aetiology of stroke among people living with HIV infection is heterogeneous and varies by the stage of HIV infection. 2 Antiretroviral therapy to some degree, HIV-driven immune dysregulation, endothelial dysfunction, and metabolic derangement are all implicated in the mechanism but the major drivers still elude us. 1 The prohibitive costs of using advanced imaging in regions where HIV is endemic has limited our understanding and progress in this field.
Dlamini et al. 3 used a low-cost, non-invasive imaging technique (transcranial Doppler [TCD]) to investigate evidence of intracranial vasculopathy in children who had HIV infection with or without a stroke. They compared this to a historical global control group who were similar in age. This study was conducted in Cape Town, South Africa where the HIV prevalence is approximately 13%. They excluded those with HIV encephalopathy, tuberculosis meningitis, and other neurological disorders. Stroke was defined using the World Health Organization clinical definition, and brain imaging was used as confirmation in most cases.
The cohort included five and 37 HIV-positive children with and without a stroke respectively. Their corresponding mean age was 7 years 3 months and 7 years 10 months. The sex distribution in the none-stroke group was well balanced but males were higher (4:1) in the stroke group. The authors used the Adam's criteria to diagnose an abnormal TCD velocity with time-averaged maximum mean velocities (TAMMVs), a proxy for intracranial stenosis. How abnormal and non-normal were defined was less clear.
The key findings were that: (1) TAMMV was higher in the stroke group than in the non-stroke group. (2) TAMMV in HIV were commonly outside the range for typically developing children. Notably, 6 out of 37 asymptomatic children with HIV had evidence of vasculopathy. (3) CD4 cell count was non-significantly lower in children with HIV and non-normal TCD, and a trend for non-normal TCD was more common in children with untreated HIV. This supports the consensus that HIV treatment and the accompanying immune restoration reduces overall stroke risk. However, the risk may not be completely aborted. Unfortunately, the numbers are too small to investigate this important issue. (4) Exposure to stroke risk factors such as hypertension, cardiac disease, and varicella zoster was described. All of which can be interlinked with HIV infection or occur independently, and could contribute to an additive or synergistic stroke risk.
Limitations to the study include: (1) a small sample size, which limits definitive conclusions. (2) The absence of screening for varicella zoster virus reactivation which is common in HIV infection and could offer an alternative explanation for the reported intracranial vasculopathy. 4 
(3)
The possibility of a high insonation failure rate in this population. 5 Despite these limitations, the authors have excelled in bringing together a technically challenging study and have demonstrated the utility of TCD in this setting. The results are consistent with observations found in adults. HIV-positive children (who are mostly infected through vertical transmission) offer a unique opportunity to understand the natural history of HIV infection and stroke, without the distraction of confounders which accompanies the ageing process found in adults. A more concerted effort is warranted so that better treatment interventions can be offered.
